Why the study?
Pulmonary veno-occlusive disease is often mistaken for pulmonary arterial hypertension, and distinguishing them is critical because vasodilator therapy in PVOD is controversial and may be fatal.
Highlights the importance of distinguishing PVOD from PAH to avoid potentially fatal vasodilator treatment.
Distinguishing PVOD from PAH remains essential to avoid fatal vasodilator use; extends sparse case literature but leaves open need for prospective validation.
Pulmonary veno-occlusive disease (PVOD) is a rare entity that is usually mistaken with pulmonary arterial hypertension (PAH) but is considered class I' of PAH. It is important to subclassify PVOD and distinguish it from PAH as treatment with vasodilators in PVOD patients is controversial and may be fatal. In this article, we describe a case of PVOD and how we diagnosed it.
No takes yet. Share an insight, caveat, or question.
Hajouli et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: